Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Leukemia Research - Tập 36 - Trang 397-400 - 2012
R. Itzykson1, S. Thépot1, O. Beyne-Rauzy2, S. Ame3, F. Isnard4, F. Dreyfus5, C. Salanoubat6, A.L. Taksin7, Y. Chelgoum8, C. Berthon9, J.V. Malfuson10, L. Legros11, N. Vey12, P. Turlure13, C. Gardin1, S. Boehrer1, L. Ades1, P. Fenaux1
1Service d’Hématogie Clinique Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), and Paris 13 University, France
2Service de Médecine Interne, Centre Hospitalier Universitaire Toulouse, France
3Service d’Hémato-oncologie, Centre Hospitalier Universitaire Strasbourg, France
4Service d’Hématologie, Hôpital Saint-Antoine, AP-HP and Paris 6 University, Paris, France
5Service d’Hématologie Clinique, Hôpital Cochin, AP-HP and Paris 5 University, France
6Service d’Hématologie, Centre Hospitalier du Sud Francilien, Corbeil, France
7Service d’Hémato-oncologie, Hôpital André Mignot, Le Chesnay, France
8Service d’Hématologie, Hôpital Edouard Herriot, Lyon, France
9Service des Maladies du Sang, Centre Hospitalier Universitaire (CHU), Lille, France
10Service d’Hématologie, Hôpital d’Instructions des Armées Percy, Clamart, France
11Service d’Hématologie, Centre Hospitalier Universitaire Nice, France
12Département d’Hématologie, Institut Paoli Calmettes, Marseille, France
13Service d’Hématologie Clinique, Centre Hospitalier Universitaire Limoges, France

Tài liệu tham khảo

Cheson, 2000, Report of an international working group to standardize response criteria for myelodysplastic syndromes, Blood, 96, 3671

Cheson, 2006, Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia, Blood, 108, 419, 10.1182/blood-2005-10-4149

Hellstrom-Lindberg, 2003, A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life, Br J Haematol, 120, 1037, 10.1046/j.1365-2141.2003.04153.x

Jadersten, 2008, Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome, J Clin Oncol, 26, 3607, 10.1200/JCO.2007.15.4906

Jadersten, 2005, Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF, Blood, 106, 803, 10.1182/blood-2004-10-3872

Park, 2008, Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience, Blood, 111, 574, 10.1182/blood-2007-06-096370

Fenaux, 2009, Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study, Lancet Oncol, 10, 223, 10.1016/S1470-2045(09)70003-8

Boehrer, 2010, Interim results of a randomized phase II trial of azacitidine (AZA) +/− EPO in lower risk myelodysplastic syndrome (MDS) resistant to an erythropoietic stimulating agent (ESA) alone, Blood (ASH Annual Meeting Abstracts), 116, 1880

Itzykson, 2011, Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine, Blood, 117, 403, 10.1182/blood-2010-06-289280

Hellstrom-Lindberg, 2008, Supportive care, growth factors, and new therapies in myelodysplastic syndromes, Blood Rev, 22, 75, 10.1016/j.blre.2007.10.003

List, 2008, Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission

Arcasoy, 2008, The non-haematopoietic biological effects of erythropoietin, Br J Haematol, 141, 14, 10.1111/j.1365-2141.2008.07014.x

Rizzo, 2010, American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer, Blood, 116, 4045, 10.1182/blood-2010-08-300541

Thông tin
Thông tin xuất bản

Leukemia Research

Tập 36

397-400

Thông tin tác giả